Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 3099Neoplasms 2443Carcinoma, Non-Small-Cell Lung 1867Prostatic Neoplasms 1619Colorectal Neoplasms 1426Lung Neoplasms 1295Multiple Myeloma 929Neoplasm Metastasis 920Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 848Ovarian Neoplasms 799Melanoma 784Carcinoma, Hepatocellular 737Stomach Neoplasms 639Brain Neoplasms 636Recurrence 633Squamous Cell Carcinoma of Head and Neck 632Head and Neck Neoplasms 609Glioblastoma 567Lymphoma 540Uterine Cervical Neoplasms 539Triple Negative Breast Neoplasms 505Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 499Hematologic Neoplasms 463Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 442Lymphoma, Non-Hodgkin 436Sarcoma 434

Interventions

trifluridine tipiracil drug combination 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
mCRC × 1 year × Clear all
NCT07543471 2026-04-24

PK similarity

Shanghai Henlius Biotech

Phase 1 Not yet recruiting
387 enrolled

mCRC

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting
37 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡